Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.
Epistemonikos ID: 79e2e489d6d5097ce396c45533d96c13612acf18
First added on: Jul 26, 2025